Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model

We have previously confirmed, using a rat mesenteric arteriole thrombolysis model, that thrombin inhibition induces endogenous thrombolysis in vivo. In addition, we have shown that thrombin-activatable fibrinolysis inhibitor (TAFI) plays a role in the down regulation of endogenous thrombolysis. However, the mechanism of endogenous thrombolysis or spontaneous plasmin generation in vivo remains unclear. It has been shown in an in vitro system that plasma kallikrein activates pro-urokinase (pro uPA) and/or plasminogen, resulting in plasmin generation. These findings suggest that spontaneous fibrinolysis might be mediated by tPA and plasma kallikrein-dependent uPA. The aim of the present study was to examine whether these mechanisms play a dominant role in endogenous thrombolysis in vivo, using our rat mesenteric arterial thrombolysis model. Argatroban infusion enhanced endogenous thrombolysis. PKSI-527, anti uPA and anti tPA IgGs suppressed argatroban-induced thrombolysis. Also, the antibody IgG preparations suppressed endogenous thrombolysis in the absence of argatroban. In the presence of PKSI-527, anti tPA IgG was more effective than anti uPA IgG in suppressing argatroban-induced thrombolysis. The results suggested that both tPA and plasma kallikrein-mediated uPA activation and tPA release contribute to endogenous fibrinolytic or thrombolytic mechanisms.

[1]  K. Oiwa,et al.  Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo. , 2002, Thrombosis Research.

[2]  A. Schmaier,et al.  Assembly of High Molecular Weight Kininogen and Activation of Prekallikrein on Cell Matrix , 2001, Thrombosis and Haemostasis.

[3]  K. Oiwa,et al.  Enhanced Thrombolysis Induced by Argatroban or Activated Protein C in the Presence or Absence of Staphylokinase, Measured in an in vivo Animal Model Using Mesenteric Arterioles , 2001, Pathophysiology of Haemostasis and Thrombosis.

[4]  P. Verhallen,et al.  An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. , 2000, Thrombosis research.

[5]  P. Klement,et al.  A Novel Approach to Arterial Thrombolysis , 1999 .

[6]  R. Giugliano,et al.  A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. , 1999, Journal of the American College of Cardiology.

[7]  M. Boffa,et al.  A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.

[8]  A. Schmaier,et al.  High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. , 1998, Blood.

[9]  J. Giddings,et al.  The differential involvement of von Willebrand factor, fibrinogen and fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. , 1997, The Japanese journal of physiology.

[10]  P. A. von dem Borne,et al.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. , 1997, The Journal of clinical investigation.

[11]  D. Vaughan,et al.  Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin , 1997, Thrombosis and Haemostasis.

[12]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[13]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[14]  K. Okada,et al.  FIBRINOLYTIC ACTIVITY IN LIVER TISSUES OF STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and experimental pharmacology & physiology. Supplement.

[15]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[16]  M. Johnstone,et al.  Platelet-Bound Prekallikrein Promotes Pro-Urokinase-Induced Clot Lysis: A Mechanism for Targeting the Factor XII Dependent Intrinsic Pathway of Fibrinolysis , 1994, Thrombosis and Haemostasis.

[17]  M. Nesheim,et al.  The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. , 1993, The Journal of biological chemistry.

[18]  J. Yamamoto,et al.  Antithrombotic effect of argatroban on the pial vessels of the rat: a study with He-Ne laser-induced thrombus formation. , 1993, Haemostasis.

[19]  J. Yamamoto,et al.  The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. , 1993, Thrombosis research.

[20]  T. Matsuda,et al.  Antithrombotic effect of ticlopidine on He-Ne laser-induced thrombus formation in rat mesenteric microvessels. , 1992, Haemostasis.

[21]  J. Schneider.  Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. , 1991, Thrombosis research.

[22]  V. Fuster,et al.  Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. , 1991, Blood.

[23]  H. Gold,et al.  Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. , 1991, Circulation.

[24]  Y. Okada,et al.  Effect of a highly selective plasma-kallikrein synthetic inhibitor on contact activation relating to kinin generation, coagulation and fibrinolysis. , 1990, Thrombosis research.

[25]  H. Gold,et al.  Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. , 1990, Circulation.

[26]  L. Harker,et al.  Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane. , 1989, Blood.

[27]  W. Schleuning,et al.  Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. , 1989, Blood.

[28]  F. Emmons,et al.  Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: Demonstration of a promoting effect by t-PA and by platelets on urokinase , 1988 .

[29]  S. Rahimtoola,et al.  Impaired fibrinolysis in coronary artery disease. , 1988, American heart journal.

[30]  J. Povlishock,et al.  Injury of brain microvessels with a helium-neon laser and Evans blue can elicit local platelet aggregation without endothelial denudation. , 1987, Archives of Pathology & Laboratory Medicine.

[31]  V. Gurewich,et al.  A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. , 1986, Thrombosis research.

[32]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[33]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[34]  M. Gilbert,et al.  Tissue plasminogen activator release in vivo in response to vasoactive agents. , 1985, Blood.

[35]  R. Carroll,et al.  Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies. , 1982, The Journal of laboratory and clinical medicine.

[36]  O. Matsuo,et al.  Comparison of the Relative Fibrinogenolytic, Fibrinolytic and Thrombolytic Properties of Tissue Plasminogen Activator and Urokinase in Vitro , 1981, Thrombosis and Haemostasis.

[37]  M. Iwamoto.  Plasminogen-Plasmin System IX. Specific Binding of Tranexamic Acid to Plasmin , 1975, Thrombosis and Haemostasis.

[38]  J. Holmgren,et al.  Quantitation of vibriocidal antibodies using agar plague techniques. , 1971, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.